Related Experiment Video
Updated: Jul 10, 2026
In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology
Published on: September 29, 2023
Imaging Transmembrane Kinetics: An Asymmetric Phthalocyanine Enables Fast Cellular Entry and Golgi Targeting for
Bingyang Liu1,2, Yuanyuan Han3, Kuizhi Chen1
1Key Laboratory of Optoelectronic Science and Technology for Medicine of Ministry of Education, Fujian Provincial Key Laboratory of Advanced Materials Oriented Chemical Engineering, Fujian Normal University, Fuzhou, China.
Researchers developed a new asymmetric silicon phthalocyanine (Chol-SiPc-PIP) to improve photodynamic therapy (PDT) by enhancing cellular uptake and Golgi targeting. This molecule shows promising results for more effective PDT treatments.
Area of Science:
- Materials Science
- Biochemistry
- Nanotechnology
Background:
- Photodynamic therapy (PDT) efficacy is limited by photosensitizer (PS) cellular uptake and organelle localization.
- Developing PSs with optimized pharmacokinetics is crucial for advancing PDT.
Purpose of the Study:
- To design and evaluate an asymmetric silicon phthalocyanine (Chol-SiPc-PIP) for enhanced cellular uptake and Golgi targeting in PDT.
- To investigate the impact of molecular asymmetry on PS subcellular pharmacokinetics.
Main Methods:
- Synthesis of asymmetric silicon phthalocyanine (Chol-SiPc-PIP) with cholesterol and piperazine moieties.
- High spatiotemporal resolution optical microscopy, including two-photon confocal laser scanning microscopy (CLSM) and fluorescence correlation spectroscopy (FCS).
- In vitro assessment of cellular uptake, Golgi accumulation, and photodynamic efficacy in MCF-7 cells.
Main Results:
- Chol-SiPc-PIP exhibited rapid cellular uptake and preferential accumulation in the Golgi apparatus.
- The piperazine group accelerated membrane translocation, enhancing cellular entry.
- Chol-SiPc-PIP demonstrated potent in vitro photodynamic activity with a low IC50 of 98 nM and good biocompatibility.
Conclusions:
- Asymmetric molecular design can effectively control PS subcellular pharmacokinetics and organelle-specific targeting.
- Chol-SiPc-PIP represents a promising PS candidate for advanced, cell-focused photodynamic therapy.
- This strategy offers a paradigm for developing next-generation PSs with translational potential.
